drugset / Trial / NCT00152685

High Dose Hyperoncotic Serum Albumin for the Treatment of the Acute Phase of Severe Head Injury

NCT00152685

Phase 2/3 Unknown 40 enrolled University Hospital, Angers
RandomizedSingle-groupSingle-blind

Summary

Experimentally high dose of hyperoncotic human serum albumin improve neurological recovery after head injury reduce cerebral edema and normalize apparent diffusion coefficient of water after ischemia reperfusion. The main hypothesis is that early administration of hyperoncotic serum albumin is able to reduce intracranial pressure for several days after severe head injury and thus reduce mortality and morbidity.

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Human serum albumin Protein / enzyme biologic

Indications